Globus Medical Inc-A 2025年季度报告

(Exact name of registrant as specified in its charter Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submittedpursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that theregistrant was required to submit such files):YesxNo¨ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period forcomplying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act):Yes¨Nox The number of shares outstanding of the issuer’s common stock (par value $0.001 per share) as of May 5, 2025 was135,379,373 Financial StatementsCondensed Consolidated Balance Sheets(Unaudited)March 31, 2025 and December31, 2024Condensed Consolidated Statements of Operations and Comprehensive Income(Unaudited) Condensed Consolidated Statements of Equity(Unaudited)Three months March ended 31, 2025 and March 31, 2024 Notes to CondensedConsolidated Financial Statements(Unaudited)Management’s Discussion and Analysis of Financial Condition and Results of Operations useful lives of assets, the outcome of litigation, recoverability of intangible assets and income taxes. We are subject to risks anduncertainties due to changes in the healthcare environment, regulatory oversight, competition, and legislation that may cause actualresults to differ from estimated results. recognizes revenue upon the transfer of goods or services to a customer at an amount that reflects the expected consideration to bereceived in exchange for those goods or services. The principles in ASC 606 are applied using the following five steps: (i) identify thecontract with a customer; (ii) identify the performance obligation(s) in the contract; (iii) determine the transaction price; (iv) allocatethe transaction price to the performance obligation(s) in the contract; and (v) recognize revenue when (or as) the Company satisfies its two categories, Musculoskeletal Solutions and Enabling Technologies. Our Musculoskeletal Solutions products consist primarily ofthe implantable devices, disposables, unique instruments, and neuromonitoring services, used in an expansive range of spine,orthopedic trauma, hip, knee and extremity procedures. The majority of our Musculoskeletal Solutions contracts have a singleperformance obligation and revenue is recognized at a point in time. For our IONM services, revenue is recognized in the period theservice is performed, which can be either at a point in time or over time, depending on how the performance obligation is defined for Our Enabling Technologies products are advanced hardware and software systems, and related technologies, that are designedto enhance a surgeon’s capabilities and streamline surgical procedures by making them less invasive, more accurate, and more obligations, including maintenance and support, and revenue is recognized as we fulfill each performance obligation, generally at thepoint in time in which the obligation is fulfilled. When a contract has multiple performance obligations, we allocate the contract’stransaction price to each performance obligation using our best estimate of the standalone selling price of each distinct good or service in the contract. Revenue associated with products holding rights of return or trade-in are recognized when the Company concludes there isnot a risk of significant revenue reversal in future periods for the expected consideration in the transaction. Our policy is to classifyshipping and handling costs billed to customers as sales and the related expenses as cost of sales.Contract Balances of each contract period, and revenue is recognized ratably over the maintenance period.The changes to contract liabilities related to deferred revenue are as follows: Beginning contract liabilitiesRevenue recognized from contract liabilities Advance consideration received during the periodEnding contract liabilities$ (f)Marketable SecuritiesOur marketable securities include municipal bonds, corporate debt securities, commercial paper, asset-backed securities, fair value of our available-for-sale securities, that does not result in recognition or reversal of an allowance for credit loss or write-down, is recorded, net of taxes, as a component of accumulated other comprehensive income or loss on our condensed consolidated balance sheets. Premiums and discounts are recognized over the life of the related security as an adjustment to yield using the straight-line method. Realized gains or losses from the sale of marketable securities are determined on a specific identification basis. Realizedgains and losses, interest income and the amortization/accretion of premiums/discounts are included as a component of other We invest in secu